Clinical Trial Update: Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating adding alemtuzumab to dose-dense CHOP for peripheral T-cell lymphomas, including angioimmunoblastic T-cell lymphoma and Extr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma
• Extranodal Nk T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Vincristine (vincristine)

Snippet

Sponsor: University of Göttingen | Conditions: Peripheral T Cell Lymphoma, Unspecified, Angioimmunoblastic Lymphadenopathy | Phase 3 | Status: UNKNOWN